ReviewMolecular neurobiology2019
Peripheral Biomarkers for Early Detection of Alzheimer's and Parkinson's Diseases.
Review in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- The incremental predictive value of biological aging indicators for cognitive impairment in older adults: a longitudinal analysis on the Mr. OS & Ms. OS cohort.Alzheimer's research & therapy · 2025Article
- Brain penetration of peripheral extracellular vesicles from Alzheimer's patients and induction of microglia activation.Journal of extracellular biology · 2025Article
- Review
- Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson's Disease.International journal of molecular sciences · 2024Article
- A novel approach to recognition of Alzheimer's and Parkinson's diseases: random subspace ensemble classifier based on deep hybrid features with a super-resolution image.PeerJ. Computer science · 2024Article
- Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer's Disease.International journal of molecular sciences · 2023Review
- Dysphagia in Parkinson Disease: Part I - Pathophysiology and Diagnostic Practices.Current physical medicine and rehabilitation reports · 2023Article
- Seed amplification assay of nasal swab extracts for accurate and non-invasive molecular diagnosis of neurodegenerative diseases.Translational neurodegeneration · 2023Review
- Characterization of Cystatin B Interactome in Saliva from Healthy Elderly and Alzheimer's Disease Patients.Life (Basel, Switzerland) · 2023Article
- Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage.International journal of molecular sciences · 2023Article
- Proteomic Identification of Saliva Proteins as Noninvasive Diagnostic Biomarkers.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Distribution of α-Synuclein Aggregation in the Peripheral Tissues.Neurochemical research · 2022Review
- Serum clinical laboratory tests and risk of incident dementia: a prospective cohort study of 407,190 individuals.Translational psychiatry · 2022Article
- Role of the Gut-Brain Axis, Gut Microbial Composition, Diet, and Probiotic Intervention in Parkinson's Disease.Microorganisms · 2022Review
- Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status.Biomedicines · 2022Review
- The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders.Translational neurodegeneration · 2022Review
- A New Perspective on Huntington's Disease: How a Neurological Disorder Influences the Peripheral Tissues.International journal of molecular sciences · 2022Review
- Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine.Frontiers in pharmacology · 2022Article
- Potential Roles of α-amylase in Alzheimer's Disease: Biomarker and Drug Target.Current neuropharmacology · 2022Review
- Man's best friend in life and death: scientific perspectives and challenges of dog brain banking.GeroScience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological disorders are found to be influencing the peripheral tissues outside CNS. Recent developments in biomarkers for CNS have emerged with various diagnostic and therapeutic shortcomings. The role of central biomarkers including CSF-based and molecular imaging-based probes are still unclear for early diagnosis of major neurological diseases. Current trends show that early detection of neurodegenerative diseases with non-invasive methods is a major focus of researchers, and the development of biomarkers aiming peripheral tissues is in demand. Alzheimer's and Parkinson's diseases are known for the progressive loss in neural structures or functions, including the neural death. Various dysfunctions of metabolic and biochemical pathways are associated with early occurrence of neuro-disorders in peripheral tissues including skin, blood cells, and eyes. This article reviews the peripheral biomarkers explored for early detection of Alzheimer's and Parkinson's diseases including blood cells, skin fibroblast, proteomics, saliva, olfactory, stomach and colon, heart and peripheral nervous system, and others. Graphical Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.